Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2024-01-02 00:00:00 ET · period of report 2024-01-02 · accession 0000950170-24-000386 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-02 | 2024-01-02 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +9,000 | 615.6K | +1% | +$18.7K |
| D | 2024-01-02 | 2024-01-02 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $0.00 | -9,000 | 520.0K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | M | A | 9,000 | $2.08 | 615,570 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-01-02 | M | D | 9,000 | $0.00 | 519,972 | D | $2.08 · — to 2029-11-13 | 9,000 Common Stock | (F1) The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. |